PTC Therapeutics Coverage Initiated at Oppenheimer (PTCT)
Research analysts at Oppenheimer initiated coverage on shares of PTC Therapeutics (NASDAQ:PTCT) in a report released on Thursday, TheFlyOnTheWall.com reports. The firm set an “outperform” rating on the stock.
Other equities research analysts have also recently issued reports about the stock. Analysts at Bank of America initiated coverage on shares of PTC Therapeutics in a research note on Tuesday, July 22nd. They set a “buy” rating and a $37.00 price target on the stock. Separately, analysts at Barclays initiated coverage on shares of PTC Therapeutics in a research note on Thursday, July 10th. They set an “overweight” rating on the stock. Finally, analysts at Roth Capital initiated coverage on shares of PTC Therapeutics in a research note on Monday, July 7th. They set a “buy” rating and a $34.00 price target on the stock. One equities research analyst has rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. PTC Therapeutics has an average rating of “Buy” and a consensus price target of $32.58.
PTC Therapeutics (NASDAQ:PTCT) traded down 8.87% on Thursday, hitting $26.42. The stock had a trading volume of 171,381 shares. PTC Therapeutics has a 1-year low of $13.15 and a 1-year high of $34.65. The stock has a 50-day moving average of $26.12 and a 200-day moving average of $24.73. The company’s market cap is $774.8 million.
PTC Therapeutics (NASDAQ:PTCT) last issued its quarterly earnings data on Tuesday, May 6th. The company reported ($0.58) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.46) by $0.12. On average, analysts predict that PTC Therapeutics will post $-3.11 earnings per share for the current fiscal year.
PTC Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of orally administered, small-molecule drugs that target post-transcriptional control processes.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.